Condition

Hepatocellular Carcinoma (HCC) clinical trials and research

• 111Clinical trials
• 8NIH research projects
• 1New in 30 days
• 27Countries

Newest Hepatocellular Carcinoma (HCC) clinical trials

All recruiting trials (111)

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• AI-guided treatment choices for advanced liver cancer

  Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.

  Recruiting at 5 sites Universitaire Ziekenhuizen KU Leuven · Anderlecht and 4 other locations · NCT07863258

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Biomarker testing to predict treatment response and recurrence in liver cancer

  This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07840092

• MRI plus diffusion and CEST imaging to map liver cancer and its immune environment

  This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07838415

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

• DNP-MRSI to predict HCC treatment response

  This study tests whether DNP-MRSI imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism in liver tumors can indicate which BCLC A–C HCC lesions will respond after locoregional therapies or systemic treatment.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07807475

• GPC3-Targeted PET Imaging with 18F-X12 in Liver Cancer

  This study tests whether the new PET tracer 18F-X12 can help detect, stage, and monitor hepatocellular carcinoma in adults.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07795437

• Liver Volume Metrics to Predict Immunotherapy Outcomes in Unresectable HCC

  This multicenter study tests whether baseline functional liver volume and total liver volume can forecast how patients with unresectable HCC respond to immunotherapy and how long they survive.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07782632

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

• Adaptive dosing of immune therapy for hepatocellular carcinoma

  This trial tests whether changing the dosing schedule of nivolumab plus ipilimumab can help people with hepatocellular carcinoma who have Child-Pugh B liver disease.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07689175

• GPC3-targeted PET/CT for suspected or confirmed liver cancer

  This study tests whether a GPC3-targeted PET/CT scan can help detect liver tumors in people with suspected or confirmed hepatocellular carcinoma, alongside MRI.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07677774

• TACE or HAIC with targeted therapy and immunotherapy for liver cancer

  This study tests whether adding targeted drugs and immunotherapy to TACE or HAIC helps people with unresectable hepatocellular carcinoma.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, None Selected · NCT07658833

• Lenalidomide Plus Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding lenalidomide to ongoing targeted therapy and immunotherapy helps people with advanced hepatocellular carcinoma who have progressed after at least two prior treatments.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07639138

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Improving Immunotherapy Use in Liver Cancer

  This study tests whether biomarkers can identify hepatocellular carcinoma patients who are more likely to respond to immunotherapy.

  Recruiting at 4 sites Universitaire Ziekenhuizen KU Leuven · Antwerp and 3 other locations · NCT07623265

• Personalized mRNA tumor vaccine plus standard therapy for high-risk recurrent solid tumors

  This early-phase study tests XH001, a personalized mRNA neoantigen vaccine, with standard adjuvant treatment in people with high-risk recurrent solid cancers after surgery to see if it’s safe and may help delay relapse.

  Recruiting at 2 sites Phase 1 Shenzhen Xinhe Biomedical · Beijing and 1 other locations · NCT07594964

• 68Ga-NYM207 PET/CT imaging to detect liver cancer

  A single-arm study tests whether 68Ga-NYM207 PET/CT safely detects hepatocellular carcinoma in adults.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing · NCT07590336

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• AI-assisted staging and treatment decisions for hepatocellular carcinoma

  This project will test whether an AI tool helps doctors more accurately stage HCC and choose treatments for adult patients with new or suspected primary liver cancer.

  Recruiting Beijing Tsinghua Chang Gung Hospital · Beijing, Changping · NCT07538882

• Personalized neoantigen mRNA vaccine plus PD-1 blocker after liver cancer surgery

  This will test whether a personalized neoantigen mRNA vaccine called iNeo-Vac-R01 given with a PD-1 inhibitor can help adults at high risk of hepatocellular carcinoma coming back after radical surgery.

  Recruiting Phase 1/2 Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07495215

• Fostrox plus lenvatinib versus lenvatinib in advanced HCC after immunotherapy

  In people whose advanced liver cancer got worse after first-line immunotherapy, this study tests whether adding fostrox to lenvatinib helps more than lenvatinib alone.

  Recruiting Phase 2 CHA University · Seongnam-si, Gyeonggi-do · NCT07493668

• IBI310 with sintilimab as first-line treatment for hepatocellular carcinoma

  This trial will test whether combining IBI310 with sintilimab works and is safe as a first-line option for people with advanced or metastatic hepatocellular carcinoma who have not received systemic therapy and are not candidates for curative local treatments.

  Recruiting Phase 2/3 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hefei, Anhui and 1 other locations · NCT07490262

• Conversion therapy with FOLFOX-HAIC, lenvatinib, and tislelizumab for HCC with VP3 PVTT

  This study tests a triple combination therapy to try to shrink tumors and PVTT in people with unresectable hepatocellular carcinoma to enable potential surgical removal.

  Recruiting Phase 2 First Hospital of China Medical University · Shenyang, Liaoning · NCT07483359

• Scout-dose check using resin microspheres before yttrium-90 treatment for liver tumors

  This test tries a small 'scout' dose of the same resin microspheres used in yttrium-90 treatment to better measure lung shunt in adults with liver cancer or liver metastases.

  Recruiting Seoul National University Hospital · Seoul · NCT07476651

• Biannual liver cancer screening with ultrasound and AFP for compensated non‑viral cirrhosis in Central Denmark

  This program will try giving people aged 40–79 with compensated non‑viral cirrhosis ultrasound scans plus AFP blood tests every six months to see if screening lowers deaths from liver cancer.

  Recruiting at 6 sites University of Aarhus · Aarhus, Central Jutland and 5 other locations · NCT07469319

• PULSAR plus Fecal Microbiota Transplantation for advanced HCC after targeted-immunotherapy

  This study tests whether adding FMT and a PULSAR radiotherapy approach to the original targeted-immunotherapy can help patients with advanced hepatocellular carcinoma who progressed after first-line therapy.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07463248

• Emotional health and outcomes for advanced liver cancer patients receiving HAIC plus targeted therapy and immunotherapy

  We will see if baseline emotional status (depressive versus non‑depressive) changes treatment outcomes in adults with BCLC stage B/C hepatocellular carcinoma getting hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07436845

• TACE with sintilimab, bevacizumab, and ipilimumab N01 for advanced liver cancer

  This trial tries a combination of TACE with sintilimab and bevacizumab plus a single dose of ipilimumab N01 given at different times to see if it is safe and helps people with advanced hepatocellular carcinoma whose tumors cannot be removed.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07422753

• Phase 1 safety and tolerability testing of CTX-10726 in advanced cancers.

  This phase 1 trial will test whether CTX-10726 given by IV every two weeks is safe and tolerable for adults with advanced or metastatic renal cell carcinoma, hepatocellular carcinoma, endometrial, or gastroesophageal cancer who have exhausted standard treatments.

  Recruiting at 8 sites Phase 1 Compass Therapeutics · Phoenix, Arizona and 7 other locations · NCT07419841

• Predicting post-surgery treatment for liver cancer using AI and whole-slide images

  Aims to see if an AI model based on postoperative tissue images and imaging data can help decide if patients with hepatocellular carcinoma should receive adjuvant therapy after surgery.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07417800

• Tislelizumab plus Huaier granule as first treatment for unresectable liver cancer

  This tests whether giving tislelizumab together with Huaier granule as a first treatment helps people with unresectable hepatocellular carcinoma.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07413354

• SBRT vs surgical removal for small liver cancer (HCC)

  This study tests whether stereotactic body radiotherapy (SBRT) can be as effective as surgical removal for small hepatocellular carcinoma in adults who are eligible for either option.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07381660

• Ondansetron to reduce immune‑therapy–related toxicities in liver cancer patients

  This trial tests whether ondansetron can lower immune checkpoint inhibitor–related side effects in adults with hepatocellular carcinoma who are receiving standard ICI therapy.

  Recruiting Phase 2 First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07381634

• Blood biomarker changes before and after TACE for hepatocellular carcinoma

  This will see if blood biomarkers change after TACE and whether those changes match early CT/MRI response in adults with hepatocellular carcinoma.

  Recruiting University of Belgrade · Belgrade · NCT07378709

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• CREPT-618 for adults with locally advanced liver cancer

  This trial will try CREPT-618, a gene therapy given by subcutaneous injection every two weeks, in adults 18–75 with locally advanced hepatocellular carcinoma who have failed standard treatments to find a safe and appropriate dose.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07364357

• Icaritin plus mFOLFOX after surgery for high-risk hepatocellular carcinoma

  This study will try giving oral Icaritin together with postoperative hepatic arterial infusion chemotherapy (mFOLFOX) to adults with hepatocellular carcinoma who have high-risk features for recurrence after curative surgery.

  Recruiting Phase 2 Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07337460

• Postoperative hepatic arterial infusion of mFOLFOX for high‑risk hepatocellular carcinoma

  This trial tests whether giving up to two courses of mFOLFOX directly into the liver artery after curative surgery can lower recurrence in adults with hepatocellular carcinoma who have high‑risk features.

  Recruiting Phase 2 Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07337421

• Sintilimab plus a bevacizumab biosimilar as adjuvant therapy after surgery for ruptured hepatocellular carcinoma

  This trial will test whether giving sintilimab together with a bevacizumab biosimilar after curative surgery can lower recurrence in adults who had a ruptured hepatocellular carcinoma and complete resection.

  Recruiting at 3 sites Phase 2 Ruijin Hospital · Sanming, Fujian and 3 other locations · NCT07331883

• ABSK-011 plus supportive care versus placebo for previously treated advanced liver cancer with FGF19 overexpression

  This trial tests whether adding ABSK-011 to best supportive care helps people with advanced hepatocellular carcinoma (HCC) whose tumors overexpress FGF19 after prior systemic therapy.

  Recruiting at 49 sites Phase 2 Abbisko Therapeutics Co, Ltd · Hefei, Anhui and 50 other locations · NCT07327034

• NWRD06 GPC3-targeted DNA vaccine after curative resection for hepatocellular carcinoma

  This study will test whether the GPC3-targeted DNA vaccine NWRD06, given by electroporation, can help prevent recurrence in adults with GPC3-positive hepatocellular carcinoma after curative surgery or ablation.

  Recruiting Phase 2 Newish Technology (Beijing) Co., Ltd. · Beijing, Beijing Municipality and 5 other locations · NCT07324304

• Comparing DEB-TACE and cTACE for liver cancer after TIPS

  This trial will test whether DEB-TACE or conventional TACE works better and is safer for people with hepatocellular carcinoma beyond Milan criteria who previously had a TIPS.

  Recruiting Phase 3 First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07322848

• Personalized computer-guided planning for radioembolization in liver cancer

  This project will try using patient-specific computer models of liver blood flow to predict where radioactive microspheres go during transarterial radioembolization for people with hepatocellular carcinoma.

  Recruiting University Hospital, Ghent · Ghent · NCT07315633

• Liquid biopsy molecular profiling of hepatocellular carcinoma after Y-90 radioembolization

  This will test whether blood liquid biopsies (circulating tumor cells and cell-free DNA) taken before and after Y-90 radioembolization can help predict which adults with hepatocellular carcinoma will respond to treatment.

  Recruiting Palo Alto Veterans Institute for Research · Palo Alto, California · NCT07303712

• Comparing TACE plus SBRT versus Y90 radioembolization with immunotherapy for large, unresectable liver cancer

  This trial will test whether giving TACE followed by focused radiation (SBRT) or Y90 radioembolization, each followed by immunotherapy (atezolizumab + bevacizumab), helps people with large, unresectable hepatocellular carcinoma stay progression-free longer.

  Recruiting Phase 2/3 Tuen Mun Hospital · Hong Kong · NCT07293468

• MRI versus ultrasound for early liver cancer detection, body composition, and decompensation risk in cirrhosis

  This project will test whether abbreviated MRI or ultrasound is better at finding early liver cancer and measuring muscle and fat in adults with cirrhosis.

  Recruiting Linkoeping University · Linköping, Select A State Or Province · NCT07291141

• Pumitamig alone or with ipilimumab for first-line advanced or unresectable liver cancer

  This trial will test whether pumitamig, alone or combined with ipilimumab, is safe and tolerable for people with advanced or unresectable hepatocellular carcinoma who have not had prior systemic therapy.

  Recruiting at 38 sites Phase 1/2 Bristol-Myers Squibb · Duarte, California and 66 other locations · NCT07291076

• TACE with QL1706 around surgery for liver cancer that goes beyond Milan criteria

  This trial tests whether giving TACE together with QL1706 around the time of surgery is safe and helpful for adults with resectable hepatocellular carcinoma that exceeds Milan criteria.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07268131

• Cell-free tsRNA signature to detect early liver cancer

  This project will test whether a blood test that measures cell-free tsRNAs can detect early-stage hepatocellular carcinoma using samples from people with confirmed HCC.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07265271

• Computer-guided microwave ablation for liver cancer

  This trial will test whether using a computer guidance program during microwave ablation helps doctors more completely treat liver cancer tumors in adults.

  Recruiting NE Scientific INC · Boston, Massachusetts and 1 other locations · NCT07226869

• Noninvasive blood miRNA test to screen for multiple gastrointestinal cancers.

  This project will test whether a blood-based microRNA panel can detect several types of gastrointestinal cancer in adults using stored blood samples.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07224750

• GKL-006 plus TACE vs TACE alone for unresectable liver cancer

  GKL-006 injections given with TACE are being tested to see if they help people with unresectable hepatocellular carcinoma more than TACE alone.

  Recruiting at 7 sites Phase 2 Beijing Gene Key Life Technology Co., Ltd · Beijing, Beijing Municipality and 6 other locations · NCT07209813

• ST-01156, a drug that degrades RBM39, for advanced solid cancers

  This trial will test whether ST-01156 is safe and shows early anti-cancer activity in adults (and some teens with Ewing sarcoma) who have advanced or metastatic solid tumors like liver, biliary tract, or Ewing sarcoma.

  Recruiting at 6 sites Phase 1 SEED Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07197554

• FOLFOX chemotherapy with atezolizumab and bevacizumab after progression on atezolizumab plus bevacizumab for advanced liver cancer

  This trial will test whether giving FOLFOX chemotherapy together with continued atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma whose cancer progressed on prior atezolizumab plus bevacizumab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07192185

• Post-surgery radiotherapy plus sintilimab versus TACE for liver cancer with narrow surgical margins

  This trial will try to see if adding radiotherapy and the immunotherapy drug sintilimab after curative liver cancer surgery prevents recurrence better than TACE in patients with narrow surgical margins and other high-risk features.

  Recruiting Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07186621

• Multiplexed PET imaging for detecting and staging liver and gastro‑entero‑pancreatic tumors

  This study will try using multiple PET tracers to see if combined scans better detect and stage hepatocellular carcinoma and gastro‑entero‑pancreatic tumors in adults.

  Recruiting Nantes University Hospital · Brest and 2 other locations · NCT07178587

• Comparing the ipilimumab biosimilar HLX13 with US-sourced YERVOY® as first-line treatment for unresectable liver cancer

  This study tests whether the ipilimumab biosimilar HLX13 works like US-sourced YERVOY® and is safe for adults with unresectable hepatocellular carcinoma who have not had prior systemic therapy.

  Recruiting at 46 sites Phase 1 Shanghai Henlius Biotech · Glendale, California and 50 other locations · NCT07176650

• AI-based CT prediction of microvascular invasion in liver cancer

  This project will test whether an AI-powered tool using preoperative multiphase CT can predict microvascular invasion in adults with hepatocellular carcinoma who are scheduled for surgery.

  Recruiting at 19 sites Chinese Academy of Sciences · Fuzhou, Fujian and 18 other locations · NCT07170345

• Apatinib and camrelizumab plus TACE before liver resection for centrally-located BCLC‑B hepatocellular carcinoma

  This trial tests whether giving apatinib and camrelizumab together with TACE before planned liver surgery can shrink tumors and improve outcomes for adults with centrally-located BCLC stage B hepatocellular carcinoma who are eligible for resection.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07154082

• Using polyene phosphatidylcholine to protect the liver after hepatectomy

  This test checks whether giving polyene phosphatidylcholine before surgery plus magnesium isoglycyrrhizinate after surgery better prevents liver injury in people having laparoscopic liver resection for hepatocellular carcinoma.

  Recruiting Phase 4 Anhui Provincial Hospital · Hefei, Anhui · NCT07150624

• Combining advanced ultrasound and molecular analyses to map tumor differences in liver cancer

  This project tries combining multiple ultrasound techniques with molecular (multi-omics) tests to see if they can better characterize tumors and guide care for adults with primary liver cancer who are scheduled for surgery.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07101237

• TUDCA with camrelizumab and regorafenib for advanced hepatocellular carcinoma after anti‑PD‑1/PD‑L1 plus bevacizumab

  This trial tests whether adding TUDCA to camrelizumab and regorafenib helps people with advanced hepatocellular carcinoma that got worse after anti‑PD‑1/PD‑L1 plus bevacizumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07100392

• HBV mRNA vaccine to lower HCC recurrence around liver transplant

  This trial will test whether an HBV-targeted mRNA vaccine can reduce hepatocellular carcinoma recurrence in adults with hepatitis B who are awaiting or undergoing liver transplantation.

  Recruiting Phase 1 West China Hospital · Chengdu · NCT07077356

• Ipilimumab and nivolumab plus focused liver radiation for locally advanced liver cancer

  This trial tests whether combining nivolumab and ipilimumab with focused liver radiation (SBRT) can help adults with locally advanced hepatocellular carcinoma, with attention to including Native Hawaiian and Pacific Islander patients.

  Recruiting Phase 1 University of Hawaii · Honolulu, Hawaii and 1 other locations · NCT07075120

• Yttrium-90 internal radiation versus hepatic arterial infusion chemotherapy for potentially resectable intermediate-to-advanced liver cancer

  This study will try whether yttrium-90 internal radiation (SIRT) or hepatic arterial infusion chemotherapy (HAIC) works better for adults with potentially resectable intermediate-to-advanced hepatocellular carcinoma.

  Recruiting First Affiliated Hospital of Jinan University · Guangzhou, Guangdong · NCT07070076

• Using AI on CT and MRI scans to predict immunotherapy response and survival for liver cancer patients

  This project will test whether artificial intelligence applied to CT and MRI scans can predict which adults with hepatocellular carcinoma will respond to immunotherapy and their likely survival.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07059936

• AK104 or AK112 plus TT-00420 for advanced hepatocellular carcinoma

  This study tests whether combining AK104 or AK112 with the oral drug TT-00420 (tinengotinib) can help adults with advanced hepatocellular carcinoma (HCC).

  Recruiting Phase 2 Akeso · Wuhan, China · NCT07052253

• Lenvatinib plus tislelizumab versus lenvatinib alone for advanced hepatocellular carcinoma after prior PD‑1/PD‑L1 plus bevacizumab

  This trial will test whether adding the immunotherapy tislelizumab to lenvatinib works better than lenvatinib alone for people with advanced liver cancer who progressed after prior PD‑1/PD‑L1 plus bevacizumab treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07047586

• Radiation therapy followed by immune therapy and surgery for hepatocellular carcinoma

  This trial tests whether adding durvalumab and tremelimumab to radiation therapy before surgery helps people with resectable liver cancer.

  Recruiting Phase 3 Hamilton Health Sciences Corporation · Hamilton, Ontario and 1 other locations · NCT07027436

• PSMA PET/CT for staging and managing hepatocellular carcinoma

  PSMA PET/CT will be tried alongside standard CT or MRI to see if it improves diagnosis, staging, and tracking of treatment response for adults with suspected or confirmed hepatocellular carcinoma.

  Recruiting at 2 sites VA Office of Research and Development · West Los Angeles, California and 1 other locations · NCT07019844

• FOLFOX with durvalumab, bevacizumab, and targeted radiation to try to make advanced liver cancer operable

  This will try combining liver-directed FOLFOX chemotherapy, durvalumab, bevacizumab, and focused radiation to see if intermediate or advanced liver cancer can be shrunk enough for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07012798

• Advanced multiparametric MRI to better describe liver cancer (HCC)

  This project will test whether advanced multiparametric MRI scans can better describe tumor features and help guide treatment for adults with confirmed or suspected hepatocellular carcinoma (HCC) who are scheduled for TACE or SIRT.

  Recruiting University Hospital Muenster · Münster · NCT06999174

• Simplified radioembolization for small liver cancer

  We will try giving radioembolization without a pre-treatment MAA scan in adults with small (≤5 cm), limited hepatocellular carcinoma and low-risk imaging features to see if the approach is safe and practical.

  Recruiting at 3 sites Seoul National University Hospital · Goyang and 4 other locations · NCT06979219

• Preventing esophageal varices in liver cancer patients treated with specific medications

  This study is testing whether treating liver cancer patients with specific medications can help prevent the worsening of esophageal varices and reduce the risk of bleeding.

  Recruiting Tanta University · Tanta, Gharbyea · NCT06961526

• Same-day treatment for large liver tumors

  This study is testing if treating large liver tumors in one day with a special procedure is safe and effective for certain patients.

  Recruiting at 2 sites Seoul National University Hospital · Goyang and 3 other locations · NCT06944483

• Digital symptom monitoring for liver cancer patients in China

  This study is testing if a digital tool that helps liver cancer patients report their symptoms weekly can improve their health and communication with doctors.

  Recruiting Peking University · Haidian, Beijing Municipality · NCT06938945

• Combining portal and hepatic vein embolization for liver cancer treatment

  This study is testing if combining two types of vein treatments can help more people with liver cancer have surgery and live longer.

  Recruiting Maastricht University · New Haven, Connecticut and 54 other locations · NCT06914648

• Evaluating a combination treatment for advanced liver cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it helps patients live longer and feel better.

  Recruiting Phase 1/2 Seoul National University Hospital · Seoul · NCT06911255

• Collecting blood and tissue samples from patients with primary liver cancer

  This study is collecting blood and tissue samples from patients with primary liver cancer to help researchers find new treatments for the disease.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT06899854

• Monitoring tumor changes and treatment response in bile duct and liver cancer patients

  This study is testing how different factors affect treatment responses in people with bile duct or liver cancer by looking at their blood and tumor samples during and after their treatment.

  Recruiting at 3 sites Region Skane · Kristianstad and 2 other locations · NCT06877637

• Examining the impact of lymph node metastasis on survival in advanced liver cancer

  This study is testing if having cancer spread to lymph nodes affects how long people with advanced liver cancer live after receiving certain treatments.

  Recruiting Zhongda Hospital · Nanjing, Jiangsu and 1 other locations · NCT06876753

• A breath test to detect liver cancer and monitor liver health

  This study is testing a new breath test to see if it can help find liver cancer earlier and keep track of liver health in adults with liver issues or certain stomach symptoms.

  Recruiting Imperial College London · London · NCT06864195

• Monitoring urine proteins to predict early recurrence of liver cancer after surgery

  This study is testing if checking urine proteins can help doctors spot early signs of liver cancer coming back after surgery, so they can start treatment sooner for patients.

  Recruiting Zhujiang Hospital · Guangzhou, Guangdong · NCT06861114

• Combining HAIC with Sintilimab and Bevacizumab for Advanced Liver Cancer

  This study is testing if a new combination of chemotherapy and two other drugs can help people with advanced liver cancer feel better compared to using just the two drugs alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06860490

• Comparing radiotherapy with early switch to second-line therapy for oligoprogressive HCC

  This study is testing whether adding radiotherapy to ongoing treatment helps people with hepatocellular carcinoma who have limited cancer growth, compared to switching to a different treatment sooner.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06841172

• Treatment for advanced liver cancer using radiofrequency electromagnetic fields

  This study is testing a new treatment that combines immune therapy with radiofrequency electromagnetic fields to see if it helps people with advanced liver cancer who can't have surgery.

  Recruiting Charite University, Berlin, Germany · Berlin · NCT06821958

• Real-life experience with immunotherapy for liver cancer treatment

  This study is testing new combinations of immunotherapy treatments for liver cancer to see how well they work and how safe they are for patients.

  Recruiting at 16 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Torrette, AN and 23 other locations · NCT06806579

• mSEPT9 biomarker to predict liver cancer in people with cirrhosis

  This study tests whether a blood biomarker called mSEPT9 can predict the development of hepatocellular carcinoma in people with cirrhosis.

  Recruiting Central Hospital, Nancy, France · Vandœuvre-lès-Nancy · NCT06778317

• Ablative radioembolization for localized hepatocellular carcinoma beyond the Up-To-7 criteria

  This study is testing a new treatment using Yttrium-90 glass microspheres for people with localized liver cancer that doesn't meet certain criteria to see if it helps shrink tumors and improve survival.

  Recruiting at 7 sites Phase 2 Seoul National University Hospital · Gangneung, Gangwon-do and 7 other locations · NCT06773845

• Effect of Lenvatinib on High-risk Liver Cancer Recurrence After Surgery

  This study is testing if the drug lenvatinib can help prevent liver cancer from coming back after surgery in patients at high risk for recurrence.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06762782

• Evaluating 68Ga-FAPI PET/CT for treating advanced liver cancer

  This study is testing if a special type of imaging can help doctors see how well treatment is working for people with advanced liver cancer.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06746194

• Hepatic arterial infusion chemotherapy and immunotherapy for liver cancer

  This study is testing a new way to treat liver cancer by combining chemotherapy and immunotherapy directly into the liver to see if it works better than standard treatments.

  Recruiting Phase 1/2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang and 1 other locations · NCT06741020

• PET/CT with zirconium‑labelled girentuximab to image CAIX in liver and gastro‑entero‑pancreatic neuroendocrine tumors

  This will test whether a PET/CT scan using zirconium‑labelled girentuximab can find CAIX‑expressing hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and gastro‑entero‑pancreatic neuroendocrine tumors in adults.

  Recruiting Nantes University Hospital · Nantes and 1 other locations · NCT06735560

• Using RYZ811 and RYZ801 to identify and treat patients with advanced liver cancer

  This study is testing a new way to find and treat people with advanced liver cancer using two agents, RYZ811 for diagnosis and RYZ801 for treatment, to see how well they work together.

  Recruiting at 13 sites Phase 1/2 RayzeBio, Inc. · Birmingham, Alabama and 12 other locations · NCT06726161

• Combining radiotherapy and immunotherapy for advanced liver cancer before transplant

  This study is testing if combining radiation therapy with immunotherapy can help people with advanced liver cancer get better and qualify for a liver transplant.

  Recruiting Phase 1/2 University Health Network, Toronto · London, Ontario and 1 other locations · NCT06725121

• Evaluating RZ-001 with Valganciclovir and Atezolizumab/Bevacizumab for Liver Cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it is safe and effective for patients with a specific type of the disease.

  Recruiting at 9 sites Phase 1/2 Rznomics, Inc. · Busan and 8 other locations · NCT06695026

• MTS105 treatment for advanced liver cancer

  This study is testing a new treatment called MTS105 for people with advanced liver cancer to see if it can help their immune system fight the cancer after other treatments haven't worked.

  Recruiting Phase 1 Peking University · Beijing · NCT06689540

• Using mitochondrial DNA in blood to monitor liver cancer recurrence

  This study is testing if looking at mitochondrial DNA in the blood can help doctors track liver cancer recurrence in patients after treatment.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06653062

• Treatment of advanced liver cancer with SN301A injection

  This study is testing if an injection called SN301A can help people with advanced liver cancer who haven’t had success with other treatments.

  Recruiting Early Phase 1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06652243

• TACE plus icaritin as adjuvant therapy after surgery for high-risk hepatocellular carcinoma

  This trial will test whether adding transarterial chemoembolization (TACE) plus oral icaritin after curative liver resection lowers 1-year recurrence in people with high-risk hepatocellular carcinoma.

  Recruiting Phase 2/3 Zhujiang Hospital · Guangzhou, Guangdong · NCT06644937

• Testing a new antibody treatment for advanced solid tumors and liver cancer

  This study is testing a new antibody treatment for people with advanced solid tumors and liver cancer to see if it is safe and how well it works.

  Recruiting at 5 sites Phase 1 Chiome Bioscience Inc. · Kashiwa, Chiba and 4 other locations · NCT06636435

• Using advanced MRI to assess treatment response in liver cancer patients

  This study is testing a special type of MRI to see if it can help doctors understand how well new treatments are working for people with liver cancer.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06605664

• Comparing endoscopic variceal ligation and carvedilol to prevent bleeding in liver cancer patients

  This study is testing whether a procedure called endoscopic variceal ligation or a daily medication called carvedilol is better at preventing bleeding in liver cancer patients with high-risk varices.

  Recruiting Phase 4 Taipei Veterans General Hospital, Taiwan · Taipei · NCT06594744

• Evaluating GI-102 for advanced solid tumors with or without other cancer drugs

  This study is testing a new cancer treatment called GI-102, both on its own and with other cancer drugs, to see how safe it is and how well it works for people with advanced solid tumors.

  Recruiting at 11 sites Phase 1/2 GI Innovation, Inc. · Scottsdale, Arizona and 10 other locations · NCT05824975

• Zanzalintinib with immune checkpoint drugs for advanced solid tumors

  This trial will test whether zanzalintinib alone or combined with immune drugs (nivolumab, with or without ipilimumab or relatlimab) is safe and helps people with advanced or metastatic solid tumors such as renal cell, prostate, urothelial, and liver cancers.

  Recruiting at 101 sites Phase 1 Exelixis · Phoenix, Arizona and 121 other locations · NCT05176483

• Evaluating liver cancer treatments and their impact on quality of life

  This study is testing how two different liver cancer treatments affect the quality of life for patients with hepatocellular carcinoma.

  Recruiting at 2 sites Duke University · Durham, North Carolina and 1 other locations · NCT04933435

• ET140203 T Cells for treating pediatric liver cancer

  This study is testing a new type of T-cell treatment for kids with certain types of liver cancer to see if it is safe and helps them feel better.

  Recruiting at 4 sites Phase 1/2 Eureka Therapeutics Inc. · Los Angeles, California and 3 other locations · NCT04634357

NIH-funded research (8)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Role of metabolic stress in NASH-related liver cancer

  This grant explores how metabolic stress linked to NASH may drive liver cancer and looks for ways to interrupt that process to help patients.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11418957

• Neoadjuvant Immunotherapy Platform for Hepatocellular Carcinoma

  A Johns Hopkins study will test immune-based therapy given before surgery to shrink liver cancer and help prevent recurrence.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11330677

• How overeating and metabolic stress drive NASH-related liver cancer

  This research looks at how excess nutrition and cell stress change liver metabolism and push NASH (fatty liver disease) toward liver cancer, with the goal of finding points to stop that process.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11189737

• Using immunotherapy before surgery to improve outcomes in liver cancer

  This study is looking at how giving immunotherapy before surgery can help boost the immune system's ability to fight liver cancer, and it's for patients with hepatocellular carcinoma who are preparing for surgery.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11093523

• Investigating how metabolic stress contributes to liver cancer development

  This study is looking at how extra weight and changes in metabolism might affect the growth of liver cancer in people with fatty liver disease, and it aims to find ways to slow down or prevent this cancer from getting worse.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-10935863

• Testing a pig model for liver cancer treatments

  This study is testing a special type of pig that has been genetically modified to develop liver cancer like humans do, to help find better treatments for people with liver cancer by seeing how different genetic changes respond to targeted therapies.

  NIH research Sus Clinicals, INC. · Cincinnati, United States · NIH-10931506

• Using advanced imaging to better understand liver cancer

  This study is looking at new ways to spot and treat liver cancer using advanced imaging techniques, which could help doctors understand your cancer better and find the best treatment just for you.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10923885

• Investigating how liver cells contribute to hepatitis B virus and liver cancer

  This study is looking at how certain parts of liver cells can help us find better ways to treat hepatitis B and liver cancer, aiming to discover new treatments that work alongside current ones to help people with chronic HBV.

  NIH research University of Illinois at Chicago · Chicago, UNITED STATES · NIH-10746092

Related topics

Quick answers

How many Hepatocellular Carcinoma (HCC) clinical trials are recruiting right now?

111, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in China (60 trials), United States (19 trials), South Korea (10 trials), Germany (6 trials), France (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 26, Phase 1/2: 11, Phase 1: 11, Phase 3: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →